Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.

Henry N GinsbergNeil J HounslowYusuke SenkoHideki SuganamiPawel BogdanskiRichard CeskaAkos KalinaRoman A LibisTatiana V SupryadkinaG Kees Hovingh

Published in: Diabetes care (2022)

Pemafibrate is effective, safe, and well-tolerated for the reduction of TG in European populations with hypertriglyceridemia despite statin treatment.

Keyphrases

end stage renal disease
cardiovascular disease
coronary artery disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
type diabetes
stem cells
bone marrow
low density lipoprotein
replacement therapy
genetic diversity